• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

骨活检在 CKD-MBD 管理中的作用。

The Role of Bone Biopsy in the Management of CKD-MBD.

机构信息

Nephrology Department, Centro Hospitalar e Universitário de Lisboa Central, Rua da Beneficência no. 8, 1050-099, Lisbon, Portugal.

Nova Medical School, Nova University, Lisbon, Portugal.

出版信息

Calcif Tissue Int. 2021 Apr;108(4):528-538. doi: 10.1007/s00223-021-00838-z. Epub 2021 Mar 26.

DOI:10.1007/s00223-021-00838-z
PMID:33772341
Abstract

A bone biopsy is still considered the gold standard for diagnosis of renal osteodystrophy. It allows to measure both static and dynamic parameters of bone remodeling and is the only method able to evaluate mineralization and allows analysis of both cortical and trabecular bone. Although bone volume can be measured indirectly by dual-energy X-ray absorptiometry, mineralization defects, bone metal deposits, cellular number/activity, and even turnover abnormalities are difficult to determine by techniques other than qualitative bone histomorphometry. In this review, we evaluate the role of bone biopsy in the clinical practice.

摘要

骨活检仍然被认为是诊断肾性骨营养不良的金标准。它可以测量骨重建的静态和动态参数,是唯一能够评估矿化并分析皮质骨和小梁骨的方法。尽管骨量可以通过双能 X 射线吸收法间接测量,但除了定性骨组织形态计量学之外,其他技术很难确定矿化缺陷、骨金属沉积、细胞数量/活性,甚至转换异常。在这篇综述中,我们评估了骨活检在临床实践中的作用。

相似文献

1
The Role of Bone Biopsy in the Management of CKD-MBD.骨活检在 CKD-MBD 管理中的作用。
Calcif Tissue Int. 2021 Apr;108(4):528-538. doi: 10.1007/s00223-021-00838-z. Epub 2021 Mar 26.
2
Changes in Bone Histomorphometry after Kidney Transplantation.肾移植后骨组织形态计量学的变化。
Clin J Am Soc Nephrol. 2019 Jun 7;14(6):894-903. doi: 10.2215/CJN.09950818. Epub 2019 May 14.
3
Racial differences in bone histomorphometry in children and young adults treated with dialysis.接受透析治疗的儿童和年轻成人骨组织形态计量学的种族差异。
Bone. 2019 Oct;127:114-119. doi: 10.1016/j.bone.2019.06.004. Epub 2019 Jun 7.
4
Recent advances in the noninvasive diagnosis of renal osteodystrophy.最近在非侵入性诊断肾性骨营养不良方面的进展。
Kidney Int. 2013 Nov;84(5):886-94. doi: 10.1038/ki.2013.254. Epub 2013 Jun 26.
5
Effects of unfractionated heparin on renal osteodystrophy and vascular calcification in chronic kidney disease rats.肝素钠对慢性肾脏病大鼠肾性骨营养不良和血管钙化的影响。
Bone. 2014 Jan;58:168-76. doi: 10.1016/j.bone.2013.10.010. Epub 2013 Oct 18.
6
Bone histomorphometry and indicators of bone and mineral metabolism in wait-listed dialysis patients.等待透析患者的骨组织形态计量学以及骨与矿物质代谢指标
Clin Nephrol. 2016 Mar;85(3):127-34. doi: 10.5414/CN108709.
7
The trabecular bone score: Relationships with trabecular and cortical microarchitecture measured by HR-pQCT and histomorphometry in patients with chronic kidney disease.骨小梁评分:与 HR-pQCT 和组织形态计量学测量的慢性肾脏病患者的骨小梁和皮质微结构的关系。
Bone. 2018 Nov;116:215-220. doi: 10.1016/j.bone.2018.08.006. Epub 2018 Aug 8.
8
Bone evaluation in paediatric chronic kidney disease: clinical practice points from the European Society for Paediatric Nephrology CKD-MBD and Dialysis working groups and CKD-MBD working group of the ERA-EDTA.儿童慢性肾脏病的骨骼评估:来自欧洲儿科学肾脏病学、CKD-MBD 和透析工作组以及 ERA-EDTA 的 CKD-MBD 工作组的临床实践要点。
Nephrol Dial Transplant. 2021 Feb 20;36(3):413-425. doi: 10.1093/ndt/gfaa210.
9
Can one evaluate bone disease in chronic kidney disease without a biopsy?能否在不进行活检的情况下评估慢性肾脏病中的骨病?
Curr Opin Nephrol Hypertens. 2014 Jul;23(4):431-7. doi: 10.1097/01.mnh.0000447014.36475.58.
10
Update on the role of bone biopsy in the management of patients with CKD-MBD.慢性肾脏病-矿物质和骨代谢异常患者骨活检在管理中的作用更新。
J Nephrol. 2017 Oct;30(5):645-652. doi: 10.1007/s40620-017-0424-8. Epub 2017 Aug 22.

引用本文的文献

1
Using Phantomless QCT for evaluating BMD evolution in maintenance hemodialysis patients.使用无体模定量CT评估维持性血液透析患者的骨密度变化
Sci Rep. 2025 Jul 1;15(1):21038. doi: 10.1038/s41598-025-07025-2.
2
Clinical approaches to osteoporosis in patients with chronic kidney disease: A comprehensive review.慢性肾脏病患者骨质疏松症的临床治疗方法:综述
Endocr J. 2025 Aug 1;72(8):847-862. doi: 10.1507/endocrj.EJ24-0271. Epub 2025 Apr 23.
3
Evaluation of Bone Biomarkers in Renal Osteodystrophy.肾性骨营养不良中骨生物标志物的评估

本文引用的文献

1
Safety of Oral Bisphosphonates in Moderate-to-Severe Chronic Kidney Disease: A Binational Cohort Analysis.中重度慢性肾脏病患者口服双膦酸盐类药物的安全性:一项跨国队列分析。
J Bone Miner Res. 2021 May;36(5):820-832. doi: 10.1002/jbmr.4235. Epub 2021 Feb 8.
2
Denosumab Safety and Efficacy Among Participants in the FREEDOM Extension Study With Mild to Moderate Chronic Kidney Disease.在 FREEDOM 扩展研究中,伴有轻度至中度慢性肾脏病的参与者中使用地舒单抗的安全性和疗效。
J Clin Endocrinol Metab. 2021 Jan 23;106(2):397-409. doi: 10.1210/clinem/dgaa851.
3
Cortical Bone Microarchitecture in Dialysis Patients.
Life (Basel). 2024 Nov 25;14(12):1540. doi: 10.3390/life14121540.
4
Comprehensive diagnostic model for osteosarcoma classification using CT imaging features.基于CT影像特征的骨肉瘤分类综合诊断模型
J Bone Oncol. 2024 Jul 13;47:100622. doi: 10.1016/j.jbo.2024.100622. eCollection 2024 Aug.
5
Vertebral fractures in patients with CKD and the general population: a call for diagnosis and action.慢性肾脏病患者与普通人群中的椎体骨折:呼吁诊断与行动。
Clin Kidney J. 2024 Jul 9;17(8):sfae191. doi: 10.1093/ckj/sfae191. eCollection 2024 Aug.
6
Ten tips on how to assess bone health in patients with chronic kidney disease.关于如何评估慢性肾病患者骨骼健康的十点建议。
Clin Kidney J. 2024 Apr 15;17(5):sfae093. doi: 10.1093/ckj/sfae093. eCollection 2024 May.
7
Evaluating Osteoporosis in Chronic Kidney Disease: Both Bone Quantity and Quality Matter.评估慢性肾脏病中的骨质疏松症:骨量和骨质量都很重要。
J Clin Med. 2024 Feb 9;13(4):1010. doi: 10.3390/jcm13041010.
8
Biochemical Clusters as Substitutes of Bone Biopsies in Kidney Transplant Patients.生化标志物聚类可替代肾移植患者的骨活检。
Calcif Tissue Int. 2024 Mar;114(3):267-275. doi: 10.1007/s00223-023-01173-1. Epub 2024 Jan 22.
9
Mixed uremic osteodystrophy: an ill-described common bone pathology in patients with chronic kidney disease.混合性尿毒症骨营养不良:慢性肾脏病患者中一种描述不足的常见骨病理状态。
Osteoporos Int. 2023 Dec;34(12):2003-2012. doi: 10.1007/s00198-023-06886-5. Epub 2023 Sep 2.
10
Relative comparison of chronic kidney disease-mineral and bone disorder rat models.慢性肾脏病-矿物质和骨异常大鼠模型的相对比较
Front Physiol. 2023 Feb 3;14:1083725. doi: 10.3389/fphys.2023.1083725. eCollection 2023.
透析患者的皮质骨微观结构。
Am J Nephrol. 2020;51(10):833-838. doi: 10.1159/000510064. Epub 2020 Sep 10.
4
Association of parathormone and alkaline phosphatase with bone turnover and mineralization in children with CKD on dialysis: effect of age, gender, and race.甲状旁腺激素和碱性磷酸酶与透析治疗的慢性肾脏病儿童的骨转换和矿化的关系:年龄、性别和种族的影响。
Pediatr Nephrol. 2020 Jul;35(7):1297-1305. doi: 10.1007/s00467-020-04499-2. Epub 2020 Mar 10.
5
Oral Bisphosphonate Use and All-Cause Mortality in Patients With Moderate-Severe (Grade 3B-5D) Chronic Kidney Disease: A Population-Based Cohort Study.口服双膦酸盐的使用与中重度(3B-5D 级)慢性肾脏病患者的全因死亡率:一项基于人群的队列研究。
J Bone Miner Res. 2020 May;35(5):894-900. doi: 10.1002/jbmr.3961. Epub 2020 Feb 18.
6
Human skeletal physiology and factors affecting its modeling and remodeling.人体骨骼生理学及影响其建模和重塑的因素。
Fertil Steril. 2019 Nov;112(5):775-781. doi: 10.1016/j.fertnstert.2019.10.005.
7
A multicenter, randomized, rater-blinded, parallel-group, phase 3 study to compare the efficacy, safety, and immunogenicity of biosimilar RGB-10 and reference once-daily teriparatide in patients with osteoporosis.一项多中心、随机、盲法、平行组、3 期研究,旨在比较生物类似药 RGB-10 与参照药物每日一次特立帕肽在骨质疏松症患者中的疗效、安全性和免疫原性。
Osteoporos Int. 2019 Oct;30(10):2027-2037. doi: 10.1007/s00198-019-05038-y. Epub 2019 Jun 26.
8
Bone-Forming and Antiresorptive Effects of Romosozumab in Postmenopausal Women With Osteoporosis: Bone Histomorphometry and Microcomputed Tomography Analysis After 2 and 12 Months of Treatment.绝经后骨质疏松症患者使用罗莫佐单抗的成骨和抗吸收作用:治疗 2 个月和 12 个月后的骨组织形态计量学和微计算机断层扫描分析。
J Bone Miner Res. 2019 Sep;34(9):1597-1608. doi: 10.1002/jbmr.3735. Epub 2019 Jun 24.
9
Bone mineral density, bone turnover markers, and incident fractures in de novo kidney transplant recipients.初诊肾移植受者的骨密度、骨转换标志物与骨折事件。
Kidney Int. 2019 Jun;95(6):1461-1470. doi: 10.1016/j.kint.2018.12.024. Epub 2019 Mar 4.
10
Effects of Denosumab and Alendronate on Bone Health and Vascular Function in Hemodialysis Patients: A Randomized, Controlled Trial.地舒单抗和阿仑膦酸钠对血液透析患者骨健康和血管功能的影响:一项随机对照试验。
J Bone Miner Res. 2019 Jun;34(6):1014-1024. doi: 10.1002/jbmr.3676. Epub 2019 Mar 4.